S. Krishnan
Net Worth
Last updated:
What is S. Krishnan net worth?
The estimated net worth of Mr. S. Krishnan is at least $25,803,498 as of 3 Sep 2025. He owns shares worth $4,071 as insider, has earned $17,849,427 from insider trading and has received compensation worth at least $7,950,000 in companies like Punjab & Sind Bank, Chennai Petroleum Corporation Limited, BioXcel Therapeutics, Inc. etc.
What is the salary of S. Krishnan?
Mr. S. Krishnan salary is $5,200,000 per year as Director of Operations & Whole-Time Director in Chennai Petroleum Corporation Limited. He also receives $1,700,000 as Chief Executive Officer, MD & Director in Punjab & Sind Bank and salaries from other companies.
How old is S. Krishnan?
Mr. S. Krishnan is 63 years old, born in 1962.
What stocks does S. Krishnan currently own?
As insider, Mr. S. Krishnan owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | Chief Digital Officer ?& Director | 800 | $5.09 | $4,071 |
What does BioXcel Therapeutics, Inc. do?
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
S. Krishnan insider trading
BioXcel Therapeutics, Inc.
Mr. S. Krishnan has made 8 insider trades between 2018-2023, according to the Form 4 filled with the SEC. Most recently he sold 60,000 units of BTAI stock worth $1,039,200 on 6 Apr 2023.
The largest trade he's ever made was exercising 473,250 units of BTAI stock on 25 Jun 2021. As of 3 Sep 2025 he still owns at least 800 units of BTAI stock.
Punjab & Sind Bank key executives
Punjab & Sind Bank executives and other stock owners filed with the SEC:
- Mr. Raghavendra Kollegal Venkatasheshan (62) Executive Director
- Mr. S. Krishnan (63) Chief Executive Officer, MD & Director